Long-term results with osimertinib after EGFR TKI failure The first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) erlotinib and gefitinib as well as the second-generation EGFR TKI afatinib are the recommended firstline options for patients with EGFR-mutant NSCLC [1]. Read more ...